We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

Biogen Inc. (BIIB), based in Cambridge, Massachusetts, is a leading biotechnology company focused on developing and ...

Allworth Financial LP lowered its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 53.6% during the fourth quarter, Holdings Channel reports. The firm owned 548 shares of the ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase “defensive ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update.

Biogen (NASDAQ:BIIB – Free Report) had its price target trimmed by HC Wainwright from $300.00 to $241.00 in a report issued ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Biogen (BIIB) and Stoke Therapeutics (STOK) announced a collaboration for the development and commercialization of zorevunersen, a potential ...

Mizuho Securities analyst Salim Syed maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $207.00.